NSE · KRSNAA · Healthcare
Krsnaa Diagnostics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹211 Cr with net profit ₹16 Cr — a 7.51% net margin, versus 25.07% the period before.
Shareholding
As of 2026-06-30
- Promoter27.11%
- Public54.09%
- FII4.28%
- DII14.51%
53,625 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.74× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #26 of 85 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,26,991 Cr | 60.36 | 13.4 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹99,959 Cr | 66.78 | 9.3 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹94,839 Cr | 101.12 | 5.77 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹67,021 Cr | 62.83 | 6.77 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,173 Cr | 170.6 | 15.73 | 8.48% | 6.54% |
| Global Health Limited | ₹38,828 Cr | 67.83 | 9.8 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹38,544 Cr | 44.72 | 8.49 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,198 Cr | 154.25 | 8.59 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹31,958 Cr | 56.82 | 12.74 | 20.13% | 18.75% |
| Molbio Diagnostics Ltd. | ₹18,257 Cr | 109.19 | 13.33 | 14.25% | 11.78% |
| Krsnaa Diagnostics Ltd.(this company) | ₹1,783 Cr | 18.3 | 1.82 | 10.35% | 11.95% |
AI analysis
AI-generated · google/gemini-2.5-flashKrsnaa Diagnostics Ltd. is listed on the Indian markets with a market capitalization of Rs 1774 Cr. The company reported a revenue of Rs 742.7 Cr and an EPS of Rs 25.65. The book value per share is Rs 274.65.
Positives
- +The debt-to-equity ratio is 0.21, indicating a low level of debt.
- +No promoter shares are reported as pledged, with promoter pledge at 0%.
Negatives
- −Promoter shareholding has decreased from 66.19% in May 2021 to 27.11% in June 2026.
- −The number of shareholders has decreased from 87,313 in August 2021 to 53,625 in June 2026.
Financial performance
In the fiscal year ending March 2025, Krsnaa Diagnostics Ltd. reported a revenue of Rs 742.695 Cr and a net profit of Rs 77.608 Cr. Quarterly results show a revenue of Rs 192.6 Cr and a net profit of Rs 41.72 Cr for the quarter ending March 2026.
Profitability & returns
The company's Return on Equity (ROE) is 9.7%, and its Return on Capital Employed (ROCE) is 10.42%. The Price-to-Earnings ratio stands at 30.62. The Earnings Per Share (EPS) for the latest reported period is Rs 25.65.
Balance sheet
Krsnaa Diagnostics Ltd. has a debt-to-equity ratio of 0.21. The book value per share is Rs 274.65. The company has a 52-week high of Rs 894.4 and a 52-week low of Rs 515.
Ownership & pledges
As of June 30, 2026, the promoter holding in Krsnaa Diagnostics Ltd. is 27.1146%. Public shareholding is 54.0877%. There are no reported promoter share pledges.
Shareholding changes
Promoter holding has decreased from 66.1872% in May 2021 to 27.1146% in June 2026. Public shareholding has increased from 33.8128% in May 2021 to 54.0877% in June 2026. The number of shareholders has decreased from 87,313 in August 2021 to 53,625 in June 2026.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.